ENTA Earnings Date: Nov 16, 2026 (Estimated) — Enanta Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is ENTA's next earnings date?
Enanta Pharmaceuticals, Inc. (ENTA) is expected to report Q4 2026 earnings on Monday, November 16, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.72 on revenue of $14.6M.
How did ENTA do in its last earnings report?
In its most recent report on Aug 10, 2026 (Q3 2026), Enanta Pharmaceuticals, Inc. posted EPS of -$0.67 versus the -$0.51 estimate, a miss of 39.6%. Revenue was $14.4M against a $16.8M estimate. The stock's 1-day post-earnings move was -2.1%.
How much does ENTA stock move after earnings?
ENTA beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.9% (up or down) in the day after earnings.
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-10 | Q3 2026 | -0.51 | -0.67 | -39.58% | $14.4M | ❌ Miss | -2.10% | -7.10% | -4.13% |
| 2026-05-11 | Q2 2026 | -0.48 | -0.45 | +6.25% | $17.2M | ✅ Beat | -6.02% | -13.00% | -24.32% |
| 2026-02-09 | Q1 2026 | -0.74 | -0.42 | +43.24% | $18.6M | ✅ Beat | +2.17% | +0.22% | +2.46% |
| 2025-11-17 | Q4 2025 | -1.06 | -0.87 | +17.92% | $15.1M | ✅ Beat | -3.59% | +6.47% | +11.15% |
| 2025-08-11 | Q3 2025 | -1.03 | -0.85 | +17.48% | $18.3M | ✅ Beat | +5.70% | +25.89% | +28.35% |
| 2025-02-10 | Q1 2025 | -1.35 | -1.05 | +22.22% | $17.0M | ✅ Beat | +14.08% | +52.86% | +48.37% |
| 2024-11-25 | Q4 2024 | -1.41 | -1.36 | +3.55% | $14.6M | ✅ Beat | -4.99% | -2.77% | -33.41% |
| 2024-02-07 | Q1 2024 | -1.19 | -1.58 | -32.77% | $18.0M | ❌ Miss | +0.82% | +7.75% | +25.61% |
Showing last 8 quarters.